SwiftScale Biologics

Developing drugs faster using the next generation of cell-free and microbial protein manufacturing methods

[SwiftScale Biologics @SwiftScaleBio]

https://t.co/FChqrJcHNQ

An article about our work to accelerate treatments for COVID-19 was recently published in GEN!

[Mark DePristo @MarkDePristo]

@AlixVentures has an excellent write-up covering the past and future of CFPS. Highlights @SwiftScaleBio and @SutroBio.

https://t.co/bvhyjUyp37.

[BIOS @bios_community]

Founder Spotlight: David Mace @ SwiftScale Biologics, a biotechnology company that enables fast protein synthesis via cell-free technology 💊🚀

https://t.co/r8lYoD81ad

[Michael C. Jewett @MichaelCJewett]

Featured by @INVOatNU for @NUSynbio developments of #cellfree biomanufacturing with @mattdelisa and @SwiftScaleBio. https://t.co/53IF3P0u5u

[SwiftScale Biologics @SwiftScaleBio]

Cheers to our academic co-founder! Well deserved

[Michael C. Jewett @MichaelCJewett]

Elected #NAI Fellow. I am so grateful for colleagues, mentors, collaborators, and students. Thank you!
@NUSynBio @NorthwesternU @NorthwesternEng @INVOatNU @StemloopInc @SwiftScaleBio

[Jacob S. Sherkow (@[email protected]) @jsherkow]

Really good thread. Answer: cell free, in vitro transcription!

[ABPDU @abpdu]

#ABPDUCanHelpYou support the fight against #COVID19.

We worked with @SwiftScaleBio and @casprbio to ramp up production of COVID-19 treatments and diagnostics. https://t.co/u0xDgAnjRI

Interested in working with us? Contact us ➡️ https://t.co/84lWJAOKTp

[Melanie Matheu, PhD @melanie_matheu]

@nonstandardcode @sethbannon @fiftyyears Those guys are great for production. Can't wait to see them grow. @SwiftScaleBio

[Seth Bannon @sethbannon]

It's beyond time to moved past animal-derived antibody production. It's slow, expensive, and cruel.

Would love to support a team building in vitro technologies for antibody generation.

Who's working on this?

https://t.co/GAU6VuqJLS

[SynBioBeta @SynBioBeta]

Typically, once antibodies are engineered, pharmaceutical companies must spend another 9+ months to optimize the manufacture and scaleup of these therapies. @SwiftScaleBio' cell-free technology cuts scale-up down to a single month. https://t.co/omOr18aSt4 #synbiobeta2020

[SwiftScale Biologics @SwiftScaleBio]

We are looking for a Site Head of Quality Assurance to join our team at SwiftScale. If you have experience in biopharmaceutical QA and want to help get more life-saving therapeutics get in the clinic more quickly please apply!
https://t.co/MIM0sc24VH

[LBNL BioSci @LBNLBioSci]

The #ABPDU is helping two #biotech companies—@casprbio & @SwiftScaleBio—scale-up production of potential diagnostics and treatments for #COVID19. Watch 🎥 ⬇️ to learn more. #BioBSE @BerkeleyLab #NatLabsInTheFight https://t.co/vCkojxKFkh

[INVO @INVOatNU]

@NorthwesternEng Prof. Michael Jewett | Going “Cell Free” Can Put a Rush on COVID-19 Antibody Therapies https://t.co/cvSCkdEY12 via @GENbio @NUSynBio @jewettlab_NU @SwiftScaleBio

[The Baker Company @TheBakerCo]

@SwiftScaleBio has created an #antibody development and #manufacturing platform that incorporates #cell free #technology.
This technology could put a rush on #covid19 antibody #therapies.
#SupportingScience
#BakerScience
Learn more:
https://t.co/YqKrjhv1ob